Various clinical studies have demonstrated that there is a close relationship between poor control of hyperglycaemia, hyperinsulinemia and diabetic complications, such as DCM.7, 30, 31, 32 Although kirenol gavage with either a 0.5 mg/kg daily dosage or 2.0 mg/kg daily dosage for 8 weeks did not affect bodyweight or lipid profiles in all groups of GK rats, oral administration of kirenol with a daily dose of 2.0 mg/kg decreased FPG levels and fasting plasma insulin by 22‐24 weeks of age in GK rats. The gene discussed is INS; the disease is familial dilated cardiomyopathy.